title: [Surfactant treatment of newborn infants with respiratory distress syndrome primarily treated with nasal continuous positive air pressure. A pilot study].
abstract: In this pilot study, Curosurf (200 mg/kg) was administrated to 34 patients with the respiratory distress syndrome in nasal-CPAP therapy with FiO2 requirements greater than 0.60 and/or TcPCO2 greater than 8 kPa. The surfactant was instilled during a short period of intubation or in a few cases via an intratracheal catheter (Ch. 6). The age of the patients on surfactant treatment ranged from two to 72 hours. Eighteen patients could be maintained on nasal-CPAP after treatment with Curosurf and only a few complications were seen in these infants. The other 16 patients subsequently required artificial ventilation and had a higher incidence of pulmonary and extrapulmonary complications. On the basis of these observations, we plan a randomized trial to investigate whether, administration of surfactant reduces the need for ventilator treatment and improves the odds for uneventful recovery in this category of patients.
authors.affiliation: Børneafdelingen, Centralsygehuset Holbaek.
authors.forename: H
authors.initials: H
authors.lastname: Verder
authors.forename: L
authors.initials: L
authors.lastname: Agertoft
authors.forename: P
authors.initials: P
authors.lastname: Albertsen
authors.forename: N C
authors.initials: NC
authors.lastname: Christensen
authors.forename: T
authors.initials: T
authors.lastname: Curstedt
authors.forename: F
authors.initials: F
authors.lastname: Ebbesen
authors.forename: G
authors.initials: G
authors.lastname: Greisen
authors.forename: N
authors.initials: N
authors.lastname: Hobolth
authors.forename: V
authors.initials: V
authors.lastname: Holm
authors.forename: T
authors.initials: T
authors.lastname: Jacobsen
mesh_terms: D001688:Biological Products; D003718:Denmark; D006801:Humans; D007231:Infant, Newborn; D010743:Phospholipids; D010865:Pilot Projects; D011175:Positive-Pressure Respiration; D011663:Pulmonary Surfactants / Q000008:administration & dosage*; D012127:Respiratory Distress Syndrome, Newborn / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy
chemical_list: D001688:Biological Products; D010743:Phospholipids; D011663:Pulmonary Surfactants; C068291:poractant alfa
vernacular_title: Surfaktantbehandling af nyfødte med respiratorisk distress-syndrom primaert behandlet med nasalt kontinuerligt positivt luftvejstryk. En pilotundersøgelse.